Microglial activation in the pathogenesis of Huntington's Disease

Frontiers in Aging Neuroscience

Volumn 9, Issue JUN, 2017, Pages

  Yang, Hui Ming ^a   Yang, Su ^b   Huang, Shan Shan ^c   Tang, Bei Sha ^a,d,e,f   Guo, Ji Feng ^a,d,e,f  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e Central South   (China)

^f National Clinical Research Center for Geriatric Medicine   (China)

Author keywords

Huntington's disease; M1 phenotype; M2 phenotype; Microglia; Microglial activation; Pathogenesis

Indexed keywords

CANNABINOID RECEPTOR; CYTOKINE; GROWTH FACTOR; HUNTINGTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KYNURENINE;

ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL INTERACTION; CELL TRANSFORMATION; DISEASE MODEL; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; MACROPHAGE; MICROGLIA; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN MISFOLDING; SIGNAL TRANSDUCTION;

EID: 85020862830     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2017.00193     Document Type: Article

References (115)

1. Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., et al. (2015). Huntington disease. Nat. Rev. Dis. Primers 1, 15005. doi: 10.1038/nrdp.2015.5
2. Benito, C., Nunez, E., Tolon, R. M., Carrier, E. J., Rabano, A., Hillard, C. J., et al. (2003). Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 23, 11136-11141
3. Benraiss, A., Wang, S., Herrlinger, S., Li, X. J., Chandler-Militello, D., Mauceri, J., et al. (2016). Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. Nat. Commun. 7:11758. doi: 10.1038/ncomms11758
4. Bisogno, T., Oddi, S., Piccoli, A., Fazio, D., and Maccarrone, M. (2016). Type-2 cannabinoid receptors in neurodegeneration. Pharmacol. Res. 111, 721-730. doi: 10.1016/j.phrs.2016.07.021
5. Bjorkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., et al. (2008). A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 205, 1869-1877. doi: 10.1084/jem.20080178
6. Blazquez, C., Chiarlone, A., Bellocchio, L., Resel, E., Pruunsild, P., Garcia-Rincon, D., et al. (2015). The CB(1) cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway. Cell Death Differ. 22, 1618-1629. doi: 10.1038/cdd.2015.11
7. Bouchard, J., Truong, J., Bouchard, K., Dunkelberger, D., Desrayaud, S., Moussaoui, S., et al. (2012). Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of huntington's disease. J. Neurosci. 32, 18259-18268. doi: 10.1523/JNEUROSCI.4008-12.2012
8. Bradford, J., Shin, J. Y., Roberts, M., Wang, C. E., Li, X. J., and Li, S. (2009). Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc. Natl. Acad. Sci. U.S.A. 106, 22480-22485. doi: 10.1073/pnas.0911503106
9. Bradford, J., Shin, J. Y., Roberts, M., Wang, C. E., Sheng, G., Li, S., et al. (2010). Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J. Biol. Chem. 285, 10653-10661. doi: 10.1074/jbc.M109.083287
10. Chang, K. H., Wu, Y. R., Chen, Y. C., and Chen, C. M. (2015). Plasma inflammatory biomarkers for Huntington's disease patients and mouse model. Brain Behav. Immun. 44, 121-127. doi: 10.1016/j.bbi.2014.09.011
11. Chang, R., Liu, X., Li, S., and Li, X. J. (2015). Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy. Drug Des. Devel. Ther. 9, 2179-2188. doi: 10.2147/DDDT.S58470
12. Chhor, V., Le Charpentier, T., Lebon, S., Ore, M. V., Celador, I. L., Josserand, J., et al. (2013). Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav. Immun. 32, 70-85. doi: 10.1016/j.bbi.2013.02.005
13. Chiarlone, A., Bellocchio, L., Blazquez, C., Resel, E., Soria-Gomez, E., Cannich, A., et al. (2014). A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc. Natl. Acad. Sci. U.S.A. 111, 8257-8262. doi: 10.1073/pnas.1400988111
14. Chiu, I. M., Morimoto, E. T. A., Goodarzi, H., Liao, J. T., O'Keeffe, S., Phatnani, H. P., et al. (2013). A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 4, 385-401. doi: 10.1016/j.celrep.2013.06.018
15. Cianciulli, A., Dragone, T., Calvello, R., Porro, C., Trotta, T., Lofrumento, D. D., et al. (2015). IL-10 plays a pivotal role in anti-inflammatory effects of resveratrol in activated microglia cells. Int. Immunopharmacol. 24, 369-376. doi: 10.1016/j.intimp.2014.12.035
16. Crotti, A., Benner, C., Kerman, B. E., Gosselin, D., Lagier-Tourenne, C., Zuccato, C., et al. (2014). Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat. Neurosci. 17, 513-521. doi: 10.1038/nn.3668
17. Crotti, A., and Glass, C. K. (2015). The choreography of neuroinflammation in Huntington's disease. Trends Immunol. 36, 364-373. doi: 10.1016/j.it.2015.04.007
18. Cunha, C., Gomes, C., Vaz, A. R., and Brites, D. (2016). Exploring new inflammatory biomarkers and pathways during LPS-induced M1 polarization. Mediators Inflamm. 2016:6986175. doi: 10.1155/2016/6986175
19. Dalrymple, A., Wild, E. J., Joubert, R., Sathasivam, K., Bjorkqvist, M., Petersen, A., et al. (2007). Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 6, 2833-2840. doi: 10.1021/pr0700753
20. Di Pardo, A., Alberti, S., Maglione, V., Amico, E., Cortes, E. P., Elifani, F., et al. (2013). Changes of peripheral TGF-beta1 depend on monocytes-derived macrophages in Huntington disease. Mol. Brain 6:55. doi: 10.1186/1756-6606-6-55
21. Diaz-Alonso, J., Paraiso-Luna, J., Navarrete, C., Del Rio, C., Cantarero, I., Palomares, B., et al. (2016). VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease. Sci. Rep. 6, 29789. doi: 10.1038/srep29789
22. DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., et al. (1997). Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993. doi: 10.1126/science.277.5334.1990
23. Donat, C. K., Fischer, F., Walter, B., Deuther-Conrad, W., Brodhun, M., Bauer, R., et al. (2014). Early increase of cannabinoid receptor density after experimental traumatic brain injury in the newborn piglet. Acta Neurobiol. Exp. (Wars) 74, 197-210
24. Donley, D. W., Olson, A. R., Raisbeck, M. F., Fox, J. H., and Gigley, J. P. (2016). Huntingtons disease mice infected with Toxoplasma gondii demonstrate early kynurenine pathway activation, altered CD8+ T-cell responses, and premature mortality. PLoS ONE 11:e0162404. doi: 10.1371/journal.pone.0162404
25. Durafourt, B. A., Moore, C. S., Zammit, D. A., Johnson, T. A., Zaguia, F., Guiot, M. C., et al. (2012). Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia 60, 717-727. doi: 10.1002/glia.22298
26. Facci, L., Barbierato, M., Marinelli, C., Argentini, C., Skaper, S. D., and Giusti, P. (2014). Toll-like receptors 2,-3 and-4 prime microglia but not astrocytes across central nervous system regions for ATP-dependent interleukin-1beta release. Sci. Rep. 4, 6824. doi: 10.1038/srep06824
27. Franciosi, S., Ryu, J. K., Shim, Y., Hill, A., Connolly, C., Hayden, M. R., et al. (2012). Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 45, 438-449. doi: 10.1016/j.nbd.2011.09.003
28. Franco, R., and Fernandez-Suarez, D. (2015). Alternatively activated microglia and macrophages in the central nervous system. Prog. Neurobiol. 131, 65-86. doi: 10.1016/j.pneurobio.2015.05.003
29. Fujigaki, H., Yamamoto, Y., and Saito, K. (2017). L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: focus on cell type differences. Neuropharmacology 112, 264-274. doi: 10.1016/j.neuropharm.2016.01.011
30. Ghosh, M., Xu, Y., and Pearse, D. D. (2016). Cyclic AMP is a key regulator of M1 to M2a phenotypic conversion of microglia in the presence of Th2 cytokines. J. Neuroinflamm. 13:9. doi: 10.1186/s12974-015-0463-9
31. Ghosh, S., and Karin, M. (2002). Missing pieces in the NF-kappaB puzzle. Cell 109, S81-S96. doi: 10.1016/S0092-8674(02)00703-1
32. Ghosh, S., May, M. J., and Kopp, E. B. (1998). NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225-260. doi: 10.1146/annurev.immunol.16.1.225
33. Giorgini, F., Guidetti, P., Nguyen, Q., Bennett, S. C., and Muchowski, P. J. (2005). A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat. Genet. 37, 526-531. doi: 10.1038/ng1542
34. Glass, M., and Northup, J. K. (1999). Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol. Pharmacol. 56, 1362-1369
35. Gomez-Nicola, D., and Perry, V. H. (2015). Microglial dynamics and role in the healthy and diseased brain: a paradigm of functional plasticity. Neuroscientist 21, 169-184. doi: 10.1177/1073858414530512
36. Graveland, G. A., Williams, R. S., and DiFiglia, M. (1985). Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227, 770-773. doi: 10.1126/science.3155875
37. Gray, M., Shirasaki, D. I., Cepeda, C., Andre, V. M., Wilburn, B., Lu, X. H., et al. (2008). Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28, 6182-6195. doi: 10.1523/JNEUROSCI.0857-08.2008
38. Gu, X., Li, C., Wei, W., Lo, V., Gong, S., Li, S. H., et al. (2005). Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46, 433-444. doi: 10.1016/j.neuron.2005.03.025
39. Guidetti, P., Bates, G. P., Graham, R. K., Hayden, M. R., Leavitt, B. R., MacDonald, M. E., et al. (2006). Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol. Dis. 23, 190-197. doi: 10.1016/j.nbd.2006.02.011
40. Guidetti, P., Luthi-Carter, R. E., Augood, S. J., and Schwarcz, R. (2004). Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis. 17, 455-461. doi: 10.1016/j.nbd.2004.07.006
41. Guillemin, G. J., Smythe, G., Takikawa, O., and Brew, B. J. (2005). Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49, 15-23. doi: 10.1002/glia.20090
42. Gutekunst, C. A., Li, S. H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., et al. (1999). Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19, 2522-2534
43. Hanisch, U. K., and Kettenmann, H. (2007). Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10, 1387-1394. doi: 10.1038/nn1997
44. Heng, M. Y., Tallaksen-Greene, S. J., Detloff, P. J., and Albin, R. L. (2007). Longitudinal evaluation of the Hdh((CAG)150) knock-in murine model of Huntington's disease. J. Neurosci. 27, 8989-8998. doi: 10.1523/JNEUROSCI.1830-07.2007
45. Heyes, M. P., Achim, C. L., Wiley, C. A., Major, E. O., Saito, K., and Markey, S. P. (1996). Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 320, 595-597. doi: 10.1042/bj3200595
46. Heyes, M. P., Saito, K., Crowley, J. S., Davis, L. E., Demitrack, M. A., Der, M., et al. (1992). Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115(Pt 5), 1249-1273. doi: 10.1093/brain/115.5.1249
47. Hodgson, J. G., Agopyan, N., Gutekunst, C. A., Leavitt, B. R., LePiane, F., Singaraja, R., et al. (1999). A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23, 181-192. doi: 10.1016/S0896-6273(00)80764-3
48. Hsiao, H. Y., Chen, Y. C., Chen, H. M., Tu, P. H., and Chern, Y. (2013). A critical role of astrocyte-mediated nuclear factor-kappaB-dependent inflammation in Huntington's disease. Hum. Mol. Genet. 22, 1826-1842. doi: 10.1093/hmg/ddt036
49. Hsiao, H. Y., Chiu, F. L., Chen, C. M., Wu, Y. R., Chen, H. M., Chen, Y. C., et al. (2014). Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease. Hum. Mol. Genet. 23, 4328-4344. doi: 10.1093/hmg/ddu151
50. Hu, X., Leak, R. K., Shi, Y., Suenaga, J., Gao, Y., Zheng, P., et al. (2015). Microglial and macrophage polarization-new prospects for brain repair. Nat. Rev. Neurol. 11, 56-64. doi: 10.1038/nrneurol.2014.207
51. Huang, B., Wei, W., Wang, G., Gaertig, M. A., Feng, Y., Wang, W., et al. (2015). Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes. Neuron 85, 1212-1226. doi: 10.1016/j.neuron.2015.02.026
52. Jack, C. S., Arbour, N., Manusow, J., Montgrain, V., Blain, M., McCrea, E., et al. (2005). TLR signaling tailors innate immune responses in human microglia and astrocytes. J. Immunol. 175, 4320-4330. doi: 10.4049/jimmunol.175.7.4320
53. Jansen, A. H., van Hal, M., Op den Kelder, I. C., Meier, R. T., de Ruiter, A. A., Schut, M. H., et al. (2017). Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific. Glia 65, 50-61. doi: 10.1002/glia.23050
54. Jha, M. K., Lee, W. H., and Suk, K. (2016). Functional polarization of neuroglia: implications in neuroinflammation and neurological disorders. Biochem. Pharmacol. 103, 1-16. doi: 10.1016/j.bcp.2015.11.003
55. Khoshnan, A., Ko, J., Watkin, E. E., Paige, L. A., Reinhart, P. H., and Patterson, P. H. (2004). Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J. Neurosci. 24, 7999-8008. doi: 10.1523/JNEUROSCI.2675-04.2004
56. Kraft, A. D., Kaltenbach, L. S., Lo, D. C., and Harry, G. J. (2012). Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons. Neurobiol. Aging 33, 621.e17-33. doi: 10.1016/j.neurobiolaging.2011.02.015
57. Kroner, A., Greenhalgh, A. D., Zarruk, J. G., Passos Dos Santos, R., Gaestel, M., and David, S. (2014). TNF and increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype in the injured spinal cord. Neuron 83, 1098-1116. doi: 10.1016/j.neuron.2014.07.027
58. Lanz, T. V., Williams, S. K., Stojic, A., Iwantscheff, S., Sonner, J. K., Grabitz, C., et al. (2017). Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis. Sci. Rep. 7:41271. doi: 10.1038/srep41271
59. Le, W. D., Wu, J. J., and Tang, Y. (2016). Protective microglia and their regulation in Parkinson's Disease. Front. Mol. Neurosci. 9:89. doi: 10.3389/fnmol.2016.00089
60. Li, H., Li, S. H., Johnston, H., Shelbourne, P. F., and Li, X. J. (2000). Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat. Genet. 25, 385-389. doi: 10.1038/78054
61. Li, S. H., Schilling, G., Young, W. S., Li, X. J., Margolis, R. L., Stine, O. C., et al. (1993). Huntingtons-Disease gene (It-15) is widely expressed in human and rat-tissues. Neuron 11, 985-993. doi: 10.1016/0896-6273(93)90127-D
62. Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481-487. doi: 10.1038/nature21029
63. Lu, B., and Palacino, J. (2013). A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration. FASEB J. 27, 1820-1829. doi: 10.1096/fj.12-219220
64. Maddison, D. C., and Giorgini, F. (2015). The kynurenine pathway and neurodegenerative disease. Semin. Cell Dev. Biol. 40, 134-141. doi: 10.1016/j.semcdb.2015.03.002
65. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., et al. (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506. doi: 10.1016/S0092-8674(00)81369-0
66. Marinelli, C., Di Liddo, R., Facci, L., Bertalot, T., Conconi, M. T., Zusso, M., et al. (2015). Ligand engagement of Toll-like receptors regulates their expression in cortical microglia and astrocytes. J. Neuroinflamm. 12, 244. doi: 10.1186/s12974-015-0458-6
67. Mecha, M., Feliu, A., Carrillo-Salinas, F. J., Rueda-Zubiaurre, A., Ortega-Gutierrez, S., de Sola, R. G., et al. (2015). Endocannabinoids drive the acquisition of an alternative phenotype in microglia. Brain Behav. Immun. 49, 233-245. doi: 10.1016/j.bbi.2015.06.002
68. Menalled, L. B., Kudwa, A. E., Miller, S., Fitzpatrick, J., Watson-Johnson, J., Keating, N., et al. (2012). Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. PLoS ONE 7:e49838. doi: 10.1371/journal.pone.0049838
69. Menalled, L. B., Sison, J. D., Dragatsis, I., Zeitlin, S., and Chesselet, M. F. (2003). Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol. 465, 11-26. doi: 10.1002/cne.10776
70. Miron, V. E., Boyd, A., Zhao, J. W., Yuen, T. J., Ruckh, J. M., Shadrach, J. L., et al. (2013). M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat. Neurosci. 16, 1211-1218. doi: 10.1038/nn.3469
71. Moller, T. (2010). Neuroinflammation in Huntington's disease. J. Neural Trans. 117, 1001-1008. doi: 10.1007/s00702-010-0430-7
72. Morganti, J. M., Riparip, L. K., and Rosi, S. (2016). Call Off the Dog(ma): M1/M2 polarization is concurrent following traumatic brain injury. PLoS ONE 11:e0148001. doi: 10.1371/journal.pone.0148001
73. Mosser, D. M., and Edwards, J. P. (2008). Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969. doi: 10.1038/nri2448
74. Ochaba, J., Monteys, A. M., O'Rourke, J. G., Reidling, J. C., Steffan, J. S., Davidson, B. L., et al. (2016). PIAS1 regulates mutant huntingtin accumulation and Huntington's Disease-associated phenotypes In Vivo. Neuron 90, 507-520. doi: 10.1016/j.neuron.2016.03.016
75. Orihuela, R., McPherson, C. A., and Harry, G. J. (2016). Microglial M1/M2 polarization and metabolic states. Br. J. Pharmacol. 173, 649-665. doi: 10.1111/bph.13139
76. Orre, M., Kamphuis, W., Dooves, S., Kooijman, L., Chan, E. T., Kirk, C. J., et al. (2013). Reactive glia show increased immunoproteasome activity in Alzheimer's disease. Brain 136, 1415-1431. doi: 10.1093/brain/awt083
77. Palazuelos, J., Aguado, T., Pazos, M. R., Julien, B., Carrasco, C., Resel, E., et al. (2009). Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132, 3152-3164. doi: 10.1093/brain/awp239
78. Pavese, N., Gerhard, A., Tai, Y. F., Ho, A. K., Turkheimer, F., Barker, R. A., et al. (2006). Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 66, 1638-1643. doi: 10.1212/01.wnl.0000222734.56412.17
79. Perry, V. H., and Holmes, C. (2014). Microglial priming in neurodegenerative disease. Nat. Rev. Neurol. 10, 217-224. doi: 10.1038/nrneurol.2014.38
80. Philips, T., and Robberecht, W. (2011). Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 10, 253-263. doi: 10.1016/S1474-4422(11)70015-1
81. Politis, M., Lahiri, N., Niccolini, F., Su, P., Wu, K., Giannetti, P., et al. (2015). Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. Neurobiol. Dis. 83, 115-121. doi: 10.1016/j.nbd.2015.08.011
82. Politis, M., Pavese, N., Tai, Y. F., Kiferle, L., Mason, S. L., Brooks, D. J., et al. (2011). Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum. Brain. Mapp. 32, 258-270. doi: 10.1002/hbm.21008
83. Ponomarev, E. D., Maresz, K., Tan, Y., and Dittel, B. N. (2007). CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J. Neurosci. 27, 10714-10721. doi: 10.1523/JNEUROSCI.1922-07.2007
84. Raper, J., Bosinger, S., Johnson, Z., Tharp, G., Moran, S. P., and Chan, A. W. (2016). Increased irritability, anxiety, and immune reactivity in transgenic Huntington's disease monkeys. Brain Behav. Immun. 58, 181-190. doi: 10.1016/j.bbi.2016.07.004
85. Rodrigues, F. B., Byrne, L. M., McColgan, P., Robertson, N., Tabrizi, S. J., Zetterberg, H., et al. (2016). Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington's Disease. PLoS ONE 11:e0163479. doi: 10.1371/journal.pone.0163479
86. Ross, C. A., and Tabrizi, S. J. (2011). Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83-98. doi: 10.1016/S1474-4422(10)70245-3
87. Sagredo, O., Gonzalez, S., Aroyo, I., Pazos, M. R., Benito, C., Lastres-Becker, I., et al. (2009). Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's Disease. Glia 57, 1154-1167. doi: 10.1002/glia.20838
88. Sapp, E., Kegel, K. B., Aronin, N., Hashikawa, T., Uchiyama, Y., Tohyama, K., et al. (2001). Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 60, 161-172. doi: 10.1093/jnen/60.2.161
89. Schatz, A. R., Lee, M., Condie, R. B., Pulaski, J. T., and Kaminski, N. E. (1997). Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol. Appl. Pharmacol. 142, 278-287. doi: 10.1006/taap.1996.8034
90. Schilling, G., Becher, M. W., Sharp, A. H., Jinnah, H. A., Duan, K., Kotzuk, J. A., et al. (1999). Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8, 397-407. doi: 10.1093/hmg/8.3.397
91. Schwarcz, R., and Pellicciari, R. (2002). Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Ther. 303, 1-10. doi: 10.1124/jpet.102.034439
92. Shechter, R., Miller, O., Yovel, G., Rosenzweig, N., London, A., Ruckh, J., et al. (2013). Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity 38, 555-569. doi: 10.1016/j.immuni.2013.02.012
93. Shin, J. Y., Fang, Z. H., Yu, Z. X., Wang, C. E., Li, S. H., and Li, X. J. (2005). Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol. 171, 1001-1012. doi: 10.1083/jcb.200508072
94. Silvestroni, A., Faull, R. L., Strand, A. D., and Moller, T. (2009). Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport 20, 1098-1103. doi: 10.1097/WNR.0b013e32832e34ee
95. Singhrao, S. K., Neal, J. W., Morgan, B. P., and Gasque, P. (1999). Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp. Neurol. 159, 362-376. doi: 10.1006/exnr.1999.7170
96. Southwell, A. L., Smith-Dijak, A., Kay, C., Sepers, M., Villanueva, E. B., Parsons, M. P., et al. (2016). An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Hum. Mol. Genet. 25, 3654-3675. doi: 10.1093/hmg/ddw212
97. Su, P., Zhang, J., Wang, D., Zhao, F., Cao, Z., Aschner, M., et al. (2016). The role of autophagy in modulation of neuroinflammation in microglia. Neuroscience 319, 155-167. doi: 10.1016/j.neuroscience.2016.01.035
98. Szalardy, L., Klivenyi, P., Zadori, D., Fulop, F., Toldi, J., and Vecsei, L. (2012). Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects. Curr. Med. Chem. 19, 1899-1920. doi: 10.2174/092986712800167365
99. Tai, Y. F., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., et al. (2007a). Imaging microglial activation in Huntington's disease. Brain Res. Bull. 72, 148-151. doi: 10.1016/j.brainresbull.2006.10.029
100. Tai, Y. F., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., et al. (2007b). Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 130, 1759-1766. doi: 10.1093/brain/awm044
101. Takeda, K., and Akira, S. (2004). TLR signaling pathways. Semin. Immunol. 16, 3-9. doi: 10.1016/j.smim.2003.10.003
102. The Huntington's Disease Collaborative Research Group' (1993). A novel gene containing a trinucleotide repeat that is expanded, and unstable on Huntington's disease chromosomes. Cell 72, 971-983
103. Trager, U., Andre, R., Lahiri, N., Magnusson-Lind, A., Weiss, A., Grueninger, S., et al. (2014). HTT-lowering reverses Huntington's disease immune dysfunction caused by NFkappaB pathway dysregulation. Brain 137, 819-833. doi: 10.1093/brain/awt355
104. Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., Munoz, E., and Sagredo, O. (2015). Neuroprotective properties of cannabigerol in Huntington's Disease: studies in R6/2 Mice and 3-nitropropionate-lesioned mice. Neurotherapeutics 12, 185-199. doi: 10.1007/s13311-014-0304-z
105. Valekova, I., Jarkovska, K., Kotrcova, E., Bucci, J., Ellederova, Z., Juhas, S., et al. (2016). Revelation of the IFNalpha, IL-10, IL-8 and IL-1beta as promising biomarkers reflecting immuno-pathological mechanisms in porcine Huntington's disease model. J. Neuroimmunol. 293, 71-81. doi: 10.1016/j.jneuroim.2016.02.012
106. Villegas-Llerena, C., Phillips, A., Garcia-Reitboeck, P., Hardy, J., and Pocock, J. M. (2016). Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. Curr. Opin. Neurobiol. 36, 74-81. doi: 10.1016/j.conb.2015.10.004
107. Walker, D. G., and Lue, L. F. (2015). Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains. Alzheimers Res. Ther. 7, 56. doi: 10.1186/s13195-015-0139-9
108. Wang, H., Liu, C., Han, M., Cheng, C., and Zhang, D. (2016). TRAM1 promotes microglia M1 polarization. J. Mol. Neurosci. 58, 287-296. doi: 10.1007/s12031-015-0678-3
109. Wang, N., Gray, M., Lu, X. H., Cantle, J. P., Holley, S. M., Greiner, E., et al. (2014). Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. Nat. Med. 20, 536-541. doi: 10.1038/nm.3514
110. Wheeler, V. C., Auerbach, W., White, J. K., Srinidhi, J., Auerbach, A., Ryan, A., et al. (1999). Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 8, 115-122. doi: 10.1093/hmg/8.1.115
111. Xu, X., Tay, Y., Sim, B., Yoon, S. I., Huang, Y., Ooi, J., et al. (2017). Reversal of phenotypic abnormalities by CRISPR/Cas9-mediated gene correction in huntington disease patient-derived induced pluripotent stem cells. Stem Cell Rep. 8, 619-633. doi: 10.1016/j.stemcr.2017.01.022
112. Zanier, E. R., Pischiutta, F., Riganti, L., Marchesi, F., Turola, E., Fumagalli, S., et al. (2014). Bone marrow mesenchymal stromal cells drive protective M2 microglia polarization after brain trauma. Neurotherapeutics 11, 679-695. doi: 10.1007/s13311-014-0277-y
113. Zeron, M. M., Hansson, O., Chen, N., Wellington, C. L., Leavitt, B. R., Brundin, P., et al. (2002). Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33, 849-860. doi: 10.1016/S0896-6273(02)00615-3
114. Zhao, T., Hong, Y., Li, S. H., and Li, X. J. (2016). Compartment-dependent degradation of mutant huntingtin accounts for its preferential accumulation in neuronal processes. J. Neurosci. 36, 8317-8328. doi: 10.1523/JNEUROSCI.0806-16.2016
115. Zwilling, D., Huang, S. Y., Sathyasaikumar, K. V., Notarangelo, F. M., Guidetti, P., Wu, H. Q., et al. (2011). Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145, 863-874. doi: 10.1016/j.cell.2011.05.020